Stay updated on Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial

Sign up to get notified when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page’s displayed revision/version number updates from **v3.5.2** to **v3.5.3**, indicating a site release without changing the trial record text.
    Difference
    0.1%
    Check dated 2026-04-24T17:10:02.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Added Revision: v3.5.2. Removed Revision: v3.5.0.
    Difference
    0.1%
    Check dated 2026-04-17T13:59:34.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Added a new Study Status section to the version history to reflect the trial's current status across revisions. An entry from 2026-03-12 was removed.
    Difference
    0.3%
    Check dated 2026-04-10T08:58:58.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    Added revision v3.5.0 and removed revision v3.4.3 from the history.
    Difference
    0.1%
    Check dated 2026-03-19T22:24:31.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    A new site revision 3.4.3 adds Oversight and Study Status entries, replacing the previous revision 3.4.2.
    Difference
    0.5%
    Check dated 2026-03-12T19:45:21.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    The page now shows revision: v3.4.2 in place of v3.4.1. This is a minor metadata update.
    Difference
    0.1%
    Check dated 2026-02-12T01:57:19.000Z thumbnail image

Stay in the know with updates to Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neratinib with Trastuzumab in ER+ HER2+ Breast Cancers Clinical Trial page.